Carrolee Barlow, MD, Ph.D. is a renowned expert in neuroscience and neurodegeneration. She is the Parkinson’s Institute and Clinical Center’s Chief Executive Officer (CEO). She joined the Parkinson’s Institute in February 2014 and is one of only two CEO’s who has run the organization since it was founded in 1988 by Dr. J. Langston.
Dr. Barlow’s career has focused on clinical care, laboratory, and clinical research, academia and industry. She is the founder and former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, Dr. Barlow was a professor at Salk Institute for Biological Studies, running a lab that used animal models to study neuro-diseases and eventually helping to establish the field of neurogenomics. After that, she supervised neuroscience biology, global exploratory, licensing and full phase efforts as the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. Moreover, she serves as an advisory board member for several biotechnology companies and disease foundations.
Dr. Barlow received her MD from the University of Utah and did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center. She went on to obtain a Ph.D. in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.
Dr. Barlow’s goal is to find solutions and treatments for Parkinson’s disease in the same way she has done with other diseases. Working with the FDA and others, she is finding ways to transform clinical studies for neurodegenerative diseases by evaluating the science and designing studies in a way that turns research into new treatments.